Education
About Us
Working with TipRanks
Follow Us
Biodesix (BDSX)
NASDAQ:BDSX
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.13Last Year’s EPS
-1.6Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented multiple strong operational and commercial positives: accelerating revenue growth, industry‑leading gross margins, the company's first positive adjusted EBITDA quarter, expanding sales coverage and strategic development partnerships. These highlights outweigh near‑term headwinds — such as seasonality, a $1M one‑time collection that partially boosted Q4 results, delayed clinical readouts for ALTITUDE, ongoing full‑year losses, and continued investment‑driven expense growth — which management is addressing through operational leverage, cash raises and loan amendments. On balance the call communicates momentum toward scaled, profitable growth while acknowledging execution and timing risks in the near term.Company Guidance
Strong Revenue Growth and Upbeat 2026 Guidance
Total revenue of $28.8M in Q4 (+41% YoY) and $88.5M for fiscal 2025 (+24% YoY). 2026 guidance of $106M–$112M (midpoint = ~23% growth vs. 2025).
Lung Diagnostics Momentum
Lung diagnostics revenue of $25.1M in Q4 (+46% YoY) and $79.2M FY (+22% YoY). Core organic lung revenue (excluding >1-year-old claims) was $24.1M in Q4 (+40% YoY). Test volumes were 18,000 in Q4 (+23% YoY) and 62,600 for the year (+15% YoY). Primary care-originated tests were 12% of Nodify orders (Q4) and grew 67% YoY; pulmonology volumes grew 26%.
Industry-Leading Gross Margins and Workflow Gains
Gross margin of 83% in Q4 and 81% for fiscal 2025, representing improvements of 400 bps and 300 bps respectively vs. prior year. Management expects margins near 80% through 2026 driven by volume mix, higher ASP and lower cost per test from workflow optimization.
First Ever Positive Adjusted EBITDA Quarter
Adjusted EBITDA of +$0.53M in Q4 (first positive quarter; +113% vs. Q4 2024). Fiscal 2025 adjusted EBITDA loss improved to -$17.5M (21% improvement YoY). Q4 net loss was -$4.0M (improved 52% YoY); FY net loss -$35.3M (improved 18% YoY).
Commercial Expansion and Salesforce Buildout
Expanded field team to 97 active sales representatives in Q4 (average 65 in Q1). Company plans to add ~6 reps per quarter (~24 for 2026) to drive penetration; historical ramp shows reps cover their costs in ~3 months.
Partnerships, Pipeline and Evidence Generation
Announced development partnerships with Thermo Fisher Scientific and Bio‑Rad Laboratories. Pipeline includes MRD combining proteomics and tumor‑informed genomics, VeriStrat expansions (immunotherapy selection, prostate), ESR1 genomic test, and AI‑based digital diagnostics. Multiple real‑world and economic data presentations and publications (AMP and collaborators) support adoption.
Stronger Liquidity Position (Pro Forma)
Unrestricted cash of $19.0M at quarter end (up 14% vs. Q3), $2.3M ATM proceeds in quarter and subsequent $14.7M ATM raise. Pro forma cash and cash equivalents reported at $33.7M; amended senior secured term loan extended to November 2028 providing additional flexibility.
BDSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BDSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $14.22 | ― | ― |
Nov 03, 2025 | $6.34 | $7.60 | +19.87% |
Aug 07, 2025 | $8.94 | $8.01 | -10.40% |
May 13, 2025 | $7.18 | $4.40 | -38.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biodesix (BDSX) report earnings?
Biodesix (BDSX) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Biodesix (BDSX) earnings time?
Biodesix (BDSX) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BDSX EPS forecast?
BDSX EPS forecast for the fiscal quarter 2026 (Q1) is -1.13.